Last reviewed · How we verify
polyvalent pneumococcal vaccine
A polyvalent pneumococcal vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae bacteria.
A polyvalent pneumococcal vaccine stimulates the immune system to produce antibodies against multiple serotypes of Streptococcus pneumoniae bacteria. Used for Prevention of invasive pneumococcal disease caused by susceptible serotypes of Streptococcus pneumoniae, Prevention of pneumococcal pneumonia.
At a glance
| Generic name | polyvalent pneumococcal vaccine |
|---|---|
| Also known as | PNEUMOVAX® 23 |
| Sponsor | Astellas Pharma Inc |
| Drug class | Polysaccharide vaccine |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains polysaccharide antigens from multiple pneumococcal serotypes, which trigger both humoral and cellular immune responses. This leads to the production of protective antibodies and memory B cells that recognize and neutralize pneumococcal pathogens upon future exposure, preventing invasive pneumococcal disease.
Approved indications
- Prevention of invasive pneumococcal disease caused by susceptible serotypes of Streptococcus pneumoniae
- Prevention of pneumococcal pneumonia
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or arthralgia
- Headache
- Fatigue
Key clinical trials
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002) (PHASE1)
- Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination (PHASE3)
- Safety and Efficacy of wSp Vaccine in Young Children (PHASE2)
- Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (PHASE4)
- A Study to Learn About How a New Pneumococcal Vaccine Works in Children (PHASE2)
- Structured Review: To Optimise Management and Prevent Harm in COPD (NA)
- Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- polyvalent pneumococcal vaccine CI brief — competitive landscape report
- polyvalent pneumococcal vaccine updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI